End-Stage Renal Disease: Symptom Management and Advance Care Planning



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2012 Apr 1;85(7):705-710.

  Patient information: See related handout on kidney failure, written by the authors of this article.

The prevalence of end-stage renal disease continues to increase, and dialysis is offered to older and more medically complex patients. Pain is problematic in up to one-half of patients receiving dialysis and may result from renal and nonrenal etiologies. Opioids can be prescribed safely, but the patient's renal function must be considered when selecting a drug and when determining the dosage. Fentanyl and methadone are considered the safest opioids for use in patients with end-stage renal disease. Nonpain symptoms are common and affect quality of life. Phosphate binders, ondansetron, and naltrexone can be helpful for pruritus. Fatigue can be managed with treatment of anemia and optimization of dialysis, but persistent fatigue should prompt screening for depression. Ondansetron, metoclopramide, and haloperidol are effective for uremia-associated nausea. Nondialytic management may be preferable to dialysis initiation in older patients and in those with additional life-limiting illnesses, and may not significantly decrease life expectancy. Delaying dialysis initiation is also an option. Patients with end-stage renal disease should have advance directives, including documentation of situations in which they would no longer want dialysis.

The number of patients with end-stage renal disease is increasing in the United States, in part because of the epidemic of diabetes mellitus. Dialysis is now offered to older and more medically complex patients who would not have been considered for treatment in the days of limited dialysis resources. The prevalence of coronary artery disease in patients receiving dialysis increased from 0.1 percent in 2004 to 21.0 percent in 2007; the prevalence of cancer and chronic obstructive pulmonary disease increased as well.1 Two-thirds of patients receiving dialysis have moderate or severe cognitive impairment.2

Symptom management and advance care planning are crucial for these patients. Family physicians may be called on to address advance directives or to support patients and families in decisions about dialysis initiation or withdrawal. In addition, family physicians must be prepared to manage symptoms associated with end-stage renal disease and adjust medication dosages appropriately.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Fentanyl and methadone are the preferred opioids for use in patients with end-stage renal disease.

C

8, 10, 11

Conservative (nondialytic) management of end-stage renal disease can be offered to older adults and patients with multiple comorbidities.

C

23, 24, 26

Delayed initiation of dialysis (when glomerular filtration rate is 5.0 to 7.0 mL per minute per 1.73 m2) yields equivalent outcomes to early initiation.

B

27

Patients with end-stage renal disease should have advance directives, including documentation of situations in which they would want to discontinue dialysis.

C

31, 34


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

View Table

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation Evidence rating References

Fentanyl and methadone are the preferred opioids for use in patients with end-stage renal disease.

C

8, 10, 11

Conservative (nondialytic) management of end-stage renal disease can be offered to older adults and patients with multiple comorbidities.

C

23, 24, 26

Delayed initiation of dialysis (when glomerular filtration rate is 5.0 to 7.0 mL per minute per 1.73 m2) yields equivalent outcomes to early initiation.

B

27

Patients with end-stage renal disease should have advance directives, including documentation of situations in which they would want to discontinue dialysis.

C

31, 34


A = consistent, good-quality patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to http://www.aafp.org/afpsort.xml.

Symptom Management

End-stage renal disease is associated with a large symptom burden. In one recent study, patients receiving dialysis reported an average of nine symptoms that resulted in impaired quality of life.3 In a second study, symptom burden and quality of life in advanced renal failure were similar to those in terminal malignancy.4 Up to one-half of symptoms of end-stage renal disease go untreated.5 In light of these findings, the United Kingdom recently adopted national guidelines for symptom management in advanced chronic kidney disease.6 Formal recommendations for renal palliative care have been slower to evolve in the United States, and symptom management is often left to family physicians.

PAIN

Pain is extremely common in end-stage renal disease and can result from renal and nonrenal etiologies. In a prospective cohort study of 205 patients receiving hemodialysis, 50 percent reported a problem with pain.7 Musculoskeletal pain was most common (63.1 percent), followed by dialysis-associated pain (13.6 percent), peripheral neuropathy (12.6 percent), and peripheral vascular disease (9.7 percent).

Some causes of pain are specific to renal disease. Polycystic kidney disease can cause chronic abdominal pain. Secondary hyperparathyroidism often results in bone pain. Calciphylaxis is a relatively rare cause of severe generalized pain that occurs almost exclusively in patients receiving dialysis. Abnormal metabolism of calcium and phosphorus leads to vascular calcification and skin ischemia, which usually presents as a painful rash or wound but can rapidly progress to overt necrosis.8 Calciphylaxis is difficult to treat and may justify withdrawal of dialysis in favor of hospice care.

Pain management must take into account the likely etiology of pain as well as the patient's renal function and dialysis status. Some analgesics should be avoided, whereas the dosage of others must be adjusted. For mild pain, acetaminophen can be used safely without any dose adjustment.8 Nonsteroidal anti-inflammatory drugs (NSAIDs) should generally be avoided in patients with end-stage renal disease because uremia causes platelet dysfunction and increases the risk of gastrointestinal bleeding. NSAIDs should always be avoided in patients receiving peritoneal dialysis.8 In this type of dialysis, adequate solute clearance and maintenance of volume balance depends on small amounts of residual renal function, which may be threatened by NSAID use.9

For moderate to severe pain, tramadol (Ultram) can be used cautiously but requires dose adjustment and an increased dosing interval; the maximal dosage should not exceed 50 to 100 mg twice daily.10 Many patients will require opioid analgesics to achieve adequate pain control. Fentanyl and methadone are considered the safest opioids for use in patients with renal failure10,11 ; other opioids may be used with close monitoring and dose adjustment (Table 16,8,10,11  and Table 211,12).

Table 1.

Opioid Selection in Patients with End-Stage Renal Disease

Drug Safety Dialysis considerations

Generally considered safe

Fentanyl

Metabolized in liver; no active metabolites

Not removed by dialysis

Methadone

Fecal excretion; no active metabolites

Not removed by dialysis

Use with caution

Hydromorphone (Dilaudid)

Mostly metabolized in liver, but one active metabolite accumulates in patients with renal failure; reduce dosage and monitor closely

Active metabolite removed by dialysis but may accumulate between sessions

Oxycodone (Roxicodone)

Mostly metabolized in liver, but small amount excreted in urine; reduce dosage and monitor closely

No data; likely to be removed by dialysis based on molecular size

Not recommended

Codeine

Metabolized to morphine; active metabolites accumulate in patients with renal failure; can cause respiratory depression, hypotension, and narcolepsy

Avoid in dialysis

Hydrocodone

Parent drug and active metabolites accumulate in patients with renal failure; no safety data

Avoid in dialysis

Meperidine (Demerol)

Active metabolite accumulates in patients with renal failure; can cause seizures

Avoid in dialysis

Morphine

Active metabolites accumulate in patients with renal failure; can cause myoclonus, seizures, and respiratory depression

Avoid, or use only when death is imminent


Information from references 6, 8, 10, and 11.

Table 1.   Opioid Selection in Patients with End-Stage Renal Disease

View Table

Table 1.

Opioid Selection in Patients with End-Stage Renal Disease

Drug Safety Dialysis considerations

Generally considered safe

Fentanyl

Metabolized in liver; no active metabolites

Not removed by dialysis

Methadone

Fecal excretion; no active metabolites

Not removed by dialysis

Use with caution

Hydromorphone (Dilaudid)

Mostly metabolized in liver, but one active metabolite accumulates in patients with renal failure; reduce dosage and monitor closely

Active metabolite removed by dialysis but may accumulate between sessions

Oxycodone (Roxicodone)

Mostly metabolized in liver, but small amount excreted in urine; reduce dosage and monitor closely

No data; likely to be removed by dialysis based on molecular size

Not recommended

Codeine

Metabolized to morphine; active metabolites accumulate in patients with renal failure; can cause respiratory depression, hypotension, and narcolepsy

Avoid in dialysis

Hydrocodone

Parent drug and active metabolites accumulate in patients with renal failure; no safety data

Avoid in dialysis

Meperidine (Demerol)

Active metabolite accumulates in patients with renal failure; can cause seizures

Avoid in dialysis

Morphine

Active metabolites accumulate in patients with renal failure; can cause myoclonus, seizures, and respiratory depression

Avoid, or use only when death is imminent


Information from references 6, 8, 10, and 11.

Table 2.

Methadone and Fentanyl Dosing in Patients with Renal Disease

Glomerular filtration rate(mL per minute per 1.73 m 2) Initial opioid dose (percentage of usual dose)
Morphine Methadone Fentanyl

> 50

100

100

100

10 to 50

50 to 75

100

75 to 100

< 10

25

50 to 75

50


Information from references 11 and 12.

Table 2.   Methadone and Fentanyl Dosing in Patients with Renal Disease

View Table

Table 2.

Methadone and Fentanyl Dosing in Patients with Renal Disease

Glomerular filtration rate(mL per minute per 1.73 m 2) Initial opioid dose (percentage of usual dose)
Morphine Methadone Fentanyl

> 50

100

100

100

10 to 50

50 to 75

100

75 to 100

< 10

25

50 to 75

50


Information from references 11 and 12.

Adjuvant medications are often added to augment opioids. Despite recent controversy about the strength of evidence for its use in neuropathic pain, gabapentin (Neurontin) is widely prescribed, and its dosage must be adjusted for renal function.13 Gabapentin is excreted unchanged in the urine; it can accumulate to potentially toxic levels in patients with renal failure. For patients receiving hemodialysis, a loading dose of 300 mg can be given, followed by 200 to 300 mg after each dialysis session.8 For patients who are not receiving dialysis but have creatinine clearance of less than 30 mL per minute per 1.73 m2, a dose of 200 to 700 mg can be given once daily.14 Tricyclic antidepressants are generally avoided in patients with chronic kidney disease; their proarrhythmic potential poses additional risk in the setting of fluctuating electrolyte abnormalities. Pregabalin (Lyrica) requires a decreased dosage and an increased dosing interval. Exact dosing depends on the indication and creatinine clearance.15

NONPAIN SYMPTOMS

Nonpain symptoms also contribute to decreased quality of life in patients with renal failure. Lack of energy and pruritus are reported by up to 75 percent of patients with stage 5 chronic kidney disease.16 More than one-half of patients have drowsiness, dyspnea, or edema16 ; additional symptoms include dry mouth, muscle cramps, restless legs syndrome, lack of appetite, poor concentration, sleep disturbance, and constipation. Many of these symptoms can be managed with simple interventions in the primary care setting (Table 3).6,8,1720 [corrected] Pruritus can be managed with phosphate binders, emollients, antihistamines, ondansetron (Zofran), and naltrexone (Revia).6,17 Fatigue can be managed by treating anemia, encouraging physical activity, and evaluating for depression.6,8 Ondansetron, metoclopramide (Reglan), and haloperidol are effective antiemetics for uremiaassociated nausea.6,19

Table 3.

Management of Common Nonpain Symptoms in Patients with End-Stage Renal Disease

Symptom Management Example initial dosages

Agitation and delirium

Haloperidol is safe and commonly used because of its rapid onset of action (reduce dosage by 50 percent); atypical antipsychotics require renal dosing; benzodiazepines are safe but may exacerbate delirium, and are widely used at the end of life

Haloperidol, 1 mg orally, intravenously, or intramuscularly every 12 hours

Anorexia

Ensure adequate dialysis (minimize uremia); evaluate for and treat depression, gastroparesis, and dry mouth; consider dronabinol (Marinol), megestrol (Megace), or prednisone

Dronabinol, 2.5 mg orally before meals

Megestrol, 400 mg orally per day

Prednisone, 10 mg orally per day

Dyspnea

Encourage regular physical activity; ensure optimal fluid balance; use opioids for refractory dyspnea at the end of life

Fentanyl, 12.5 mcg intravenously or subcutaneously every two hours as needed

Morphine, 5 mg orally or sublingually; use as needed when death is imminent

Fatigue

Ensure adequate treatment of anemia; encourage regular physical activity; evaluate for and treat depression

Fluoxetine (Prozac), 20 mg orally per day

Sertraline (Zoloft), 50 mg orally per day

Nausea and vomiting

Ensure adequate dialysis (minimize uremia); ondansetron (Zofran) is safe at usual dosages; consider metoclopramide (Reglan; reduce dosage by 50 percent); consider low-dose haloperidol for persistent nausea

Ondansetron, 4 mg orally every eight hours

Metoclopramide, 5 mg twice per day

Haloperidol, 0.5 mg orally every eight hours

Pruritus

Ensure adequate dialysis (minimize uremia); encourage compliance with phosphate binders; use emollients liberally; consider antihistamines, ondansetron, or naltrexone (Revia); ultraviolet B phototherapy may be used

Hydroxyzine (Vistaril), 25 mg orally every six hours

Ondansetron, 4 mg orally every eight hours

Naltrexone, 50 mg orally per day

Sexual dysfunction

Consider evaluation for low testosterone levels; evaluate for and treat depression; phosphodiesterase inhibitors are safe if not otherwise contraindicated

Sildenafil (Viagra), 25 mg orally before intercourse

Sleep disturbance

Treat pain; evaluate for and treat restless legs syndrome and sleep apnea; avoid caffeinated beverages and tobacco; minimize daytime naps; benzodiazepines and zolpidem (Ambien) are safe when indicated in patients undergoing dialysis

Temazepam (Restoril), 15 mg orally at bedtime

Zolpidem, 5 mg orally at bedtime


Information from references 6, 8, and 17 through 20.

Table 3.   Management of Common Nonpain Symptoms in Patients with End-Stage Renal Disease

View Table

Table 3.

Management of Common Nonpain Symptoms in Patients with End-Stage Renal Disease

Symptom Management Example initial dosages

Agitation and delirium

Haloperidol is safe and commonly used because of its rapid onset of action (reduce dosage by 50 percent); atypical antipsychotics require renal dosing; benzodiazepines are safe but may exacerbate delirium, and are widely used at the end of life

Haloperidol, 1 mg orally, intravenously, or intramuscularly every 12 hours

Anorexia

Ensure adequate dialysis (minimize uremia); evaluate for and treat depression, gastroparesis, and dry mouth; consider dronabinol (Marinol), megestrol (Megace), or prednisone

Dronabinol, 2.5 mg orally before meals

Megestrol, 400 mg orally per day

Prednisone, 10 mg orally per day

Dyspnea

Encourage regular physical activity; ensure optimal fluid balance; use opioids for refractory dyspnea at the end of life

Fentanyl, 12.5 mcg intravenously or subcutaneously every two hours as needed

Morphine, 5 mg orally or sublingually; use as needed when death is imminent

Fatigue

Ensure adequate treatment of anemia; encourage regular physical activity; evaluate for and treat depression

Fluoxetine (Prozac), 20 mg orally per day

Sertraline (Zoloft), 50 mg orally per day

Nausea and vomiting

Ensure adequate dialysis (minimize uremia); ondansetron (Zofran) is safe at usual dosages; consider metoclopramide (Reglan; reduce dosage by 50 percent); consider low-dose haloperidol for persistent nausea

Ondansetron, 4 mg orally every eight hours

Metoclopramide, 5 mg twice per day

Haloperidol, 0.5 mg orally every eight hours

Pruritus

Ensure adequate dialysis (minimize uremia); encourage compliance with phosphate binders; use emollients liberally; consider antihistamines, ondansetron, or naltrexone (Revia); ultraviolet B phototherapy may be used

Hydroxyzine (Vistaril), 25 mg orally every six hours

Ondansetron, 4 mg orally every eight hours

Naltrexone, 50 mg orally per day

Sexual dysfunction

Consider evaluation for low testosterone levels; evaluate for and treat depression; phosphodiesterase inhibitors are safe if not otherwise contraindicated

Sildenafil (Viagra), 25 mg orally before intercourse

Sleep disturbance

Treat pain; evaluate for and treat restless legs syndrome and sleep apnea; avoid caffeinated beverages and tobacco; minimize daytime naps; benzodiazepines and zolpidem (Ambien) are safe when indicated in patients undergoing dialysis

Temazepam (Restoril), 15 mg orally at bedtime

Zolpidem, 5 mg orally at bedtime


Information from references 6, 8, and 17 through 20.

Initiation of Dialysis

The decision to initiate dialysis is usually made by a nephrologist, but family physicians are ideally positioned to collaborate with nephrologists and counsel patients and families when decision making is difficult. This may be especially important when the patient is older or when there are additional life-limiting diseases.

CONSERVATIVE (NONDIALYTIC) MANAGEMENT

In response to the aging population and trends of dialyzing older and sicker patients, there has been growing interest in nondialytic alternatives for managing end-stage renal disease. The Renal Physicians Association and the American Society of Nephrology issued a practice guideline affirming the rights of patients to decline dialysis.21 Nondialytic management includes careful attention to fluid balance, treatment of anemia, and correction of acidosis and hyperkalemia. Blood pressure and metabolism of calcium and phosphorus must also be monitored. There is emerging evidence that dietary modifications may be helpful in prolonging life and decreasing symptoms.22

Patients, families, and some medical professionals may erroneously think that choosing not to start dialysis is equivalent to stopping dialysis. Although patients who discontinue dialysis die within one to two weeks, patients who decline dialysis initiation can live for months to years. Studies have showed that patients who refuse dialysis have a median life expectancy of 6.3 to 23.4 months.23,24 Functional status generally remains stable until the last month of life.25 Several studies have found little or no survival benefit with dialysis versus conservative management in older patients.23,26 Any modest survival benefit from dialysis decreases with the presence of comorbid conditions, especially ischemic heart disease.26 Family physicians can counsel older patients and those with multiple comorbidities that nondialytic management is a viable option in end-stage renal disease.

DELAYED INITIATION

Considerable clinical variation exists in the timing of dialysis initiation. A recent trial randomized 828 adults to early initiation of dialysis (at a glomerular filtration rate of 10.0 to 14.0 mL per minute per 1.73 m2) or late initiation (at 5.0 to 7.0 mL per minute per 1.73 m2).27

In three years of follow-up, there were no differences between groups in mortality, cardiovascular events, infections, or dialysis complications. This trial suggests that delayed dialysis initiation is an acceptable option, especially in patients who are unsure that they want dialysis. Delayed initiation may also be practical in patients for whom dialysis would be a significant hardship, such as those who work or have limited social support.

Advance Care Planning

The five-year survival rate for patients with stage 5 chronic kidney disease is 38 percent, less than that of AIDS and many cancers.28 For patients older than 65 years, the five-year survival rate is only 18 percent.1 Given this high mortality, advance care planning is a critical topic to address at all opportunities, such as annual physicals, hospital admissions, and routine office visits.

CARDIOPULMONARY RESUSCITATION

Patients with renal failure have poor outcomes after cardiopulmonary resuscitation (CPR). In one study of 74 patients receiving dialysis who underwent CPR for cardiopulmonary arrest, only 8 percent survived to hospital discharge, and only 3 percent were alive six months after CPR.29 These outcomes were significantly worse than those in patients who were not receiving dialysis (12 percent survival to hospital discharge, 9 percent survival six months after CPR). Patients who survive CPR often have neurologic compromise or need ongoing mechanical ventilation.

Despite these statistics, many patients with end-stage renal disease have unrealistically optimistic expectations of CPR. In one study, 87 percent of patients receiving dialysis reported that they would want CPR in the event of cardiopulmonary arrest.30 Blacks were significantly more likely to want CPR than whites (adjusted odds ratio = 6.56, 95% confidence interval, 2.57 to 22.27). Family physicians can help educate patients about the low likelihood of successful CPR in the setting of end-stage renal disease. They can also document do-not-resuscitate status if necessary.

ADVANCE DIRECTIVES

Advance directives (i.e., a living will and durable power of attorney for health care) can guide physicians in end-of-life decision making. In addition, patients who complete written advance directives are more likely to informally discuss their wishes for specific medical interventions with their families.31 As many as one-half of patients who receive dialysis do not have advance directives.32 One study showed that less than 10 percent of patients had discussions about end-of-life care with their physicians, and 61 percent reported that they regretted their decision to start dialysis.33

Most advance directives do not describe situations in which a patient would no longer want dialysis. Withdrawal of dialysis is common in end-stage renal disease; therefore, disease-specific advance directives that include dialysis withdrawal have been proposed.34 Family physicians can facilitate preemptive conversations about these issues with patients and their decision makers.

HOSPICE ELIGIBILITY

Patients whose only life-limiting diagnosis is end-stage renal disease are not eligible for the Medicare hospice benefit while they are receiving dialysis. If patients have another terminal diagnosis, they may receive concurrent hospice and dialysis benefits under Medicare. For example, a patient receiving dialysis who develops metastatic cancer may continue dialysis while receiving hospice services for cancer.35 Patients who stop dialysis are always eligible for hospice care and should be routinely referred. However, only 41.9 percent of patients who withdrew from dialysis in 2001 and 2002 received hospice services.36 Hospice care decreases the cost of care and increases the likelihood of dying at home after dialysis withdrawal.36

Data Sources: A Medline search was conducted using the key terms end-stage renal disease and kidney failure, chronic. The search included meta-analyses, randomized controlled trials, clinical trials, and reviews. The results were then combined with the following search terms: pain, palliative care, advance care planning, quality of life, and terminal care. Also searched were the Cochrane Database, the National Guideline Clearinghouse, Essential Evidence Plus, and Fast Facts for Palliative Care. Search date: January 28, 2011.

The Authors

NINA R. O'CONNOR, MD, is a staff physician at Arkansas Hospice, Little Rock.

AMY M. CORCORAN, MD, CMD, is an assistant professor of clinical medicine in the Department of Geriatrics, associate director of the geriatrics fellowship program, and associate director of the palliative medicine fellowship program at the University of Pennsylvania Perelman School of Medicine, Philadelphia.

Address correspondence to Nina R. O'Connor, MD, Arkansas Hospice, 14 Parkstone Cir., North Little Rock, AR 72116 (e-mail: noconnor@arkansashospice.org). Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations to disclose.

REFERENCES

1. US Renal Data System USRDS 2011 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States Bethesda, Md.: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2011.

2. Murray AM. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis. 2008;15(2):123–132.

3. Yong DS, Kwok AO, Wong DM, Suen MH, Chen WT, Tse DM. Symptom burden and quality of life in end-stage renal disease: a study of 179 patients on dialysis and palliative care. Palliat Med. 2009;23(2):111–119.

4. Saini T, Murtagh FE, Dupont PJ, McKinnon PM, Hatfield P, Saunders Y. Comparative pilot study of symptoms and quality of life in cancer patients and patients with end stage renal disease. Palliat Med. 2006;20(6):631–636.

5. Claxton RN, Blackhall L, Weisbord SD, Holley JL. Undertreatment of symptoms in patients on maintenance hemodialysis. J Pain Symptom Manage. 2010;39(2):211–218.

6. Douglas C, Murtagh FE, Chambers EJ, Howse M, Ellershaw J. Symptom management for the adult patient dying with advanced chronic kidney disease: a review of the literature and development of evidence-based guidelines by a United Kingdom Expert Consensus Group. Palliat Med. 2009;23(2):103–110.

7. Davison SN. Pain in hemodialysis patients: prevalence, cause, severity, and management. Am J Kidney Dis. 2003;42(6):1239–1247.

8. Cohen LM, Moss AH, Weisbord SD, Germain MJ. Renal palliative care. J Palliat Med. 2006;9(4):977–992.

9. Pastan S, Bailey J. Dialysis therapy. NEnglJMed. 1998;338(20):1428–1437.

10. Murtagh FE, Chai MO, Donohoe P, Edmonds PM, Higginson IJ. The use of opioid analgesia in end-stage renal disease patients managed without dialysis: recommendations for practice. J Pain Palliat Care Pharmacother. 2007;21(2):5–16.

11. Dean M. Opioids in renal failure and dialysis patients. J Pain Symptom Manage. 2004;28(5):497–504.

12. Aronoff GR, Berns JS, Brier ME, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults. 4th ed. Philadelphia, Pa.: American College of Physicians; 1999.

13. Landefeld CS, Steinman MA. The Neurontin legacy—marketing through misinformation and manipulation. N Engl J Med. 2009;360(2):103–106.

14. Neurontin (gabapentin) [prescribing information]. New York, NY: Pfizer; 2011. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=52049. Accessed September 16, 2011.

15. Lyrica (pregabalin) [prescribing information]. New York, NY: Pfizer; 2011.http://labeling.pfizer.com/ShowLabeling.aspx?id=561. Accessed September 16, 2011.

16. Murtagh FE, Addington-Hall JM, Edmonds PM, et al. Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney disease managed without dialysis. J Palliat Med. 2007;10(6):1266–1276.

17. Murtagh FE, Addington-Hall JM, Donohoe P, Higginson IJ. Symptom management in patients with established renal failure managed without dialysis. EDTNA ERCA J. 2006;32(2):93–98.

18. Murtagh FE, Murphy E, Shepherd KA, Donohoe P, Edmonds PM. End-of-life care in end-stage renal disease: renal and palliative care. Br J Nurs. 2006;15(1):8–11.

19. Critchley P, Plach N, Grantham M, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manage. 2001;22(2):631–634.

20. Cohen LM, Tessier EG, Germain MJ, Levy NB. Update on psychotropic medication use in renal disease. Psychosomatics. 2004;45(1):34–48.

21. Galla JH; Renal Physicians Association; American Society of Nephrology. Clinical practice guideline on shared decision-making in the appropriate initiation of and withdrawal from dialysis [published correction appears in J Am Soc Nephrol. 2000;11(9):2 p following 1788]. J Am Soc Nephrol. 2000;11(7):1340–1342.

22. Brunori G, Viola BF, Parrinello G, et al. Efficacy and safety of a very-low-protein diet when postponing dialysis in the elderly: a prospective randomized multicenter controlled study. Am J Kidney Dis. 2007;49(5):569–580.

23. Smith C, Da Silva-Gane M, Chandna S, Warwicker P, Greenwood R, Farrington K. Choosing not to dialyse: evaluation of planned nondialytic management in a cohort of patients with end-stage renal failure. Nephron Clin Pract. 2003;95(2):c40–c46.

24. Wong CF, McCarthy M, Howse ML, Williams PS. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis [published correction appears in Ren Fail. 2008;30(3):343]. Ren Fail. 2007;29(6):653–659.

25. Murtagh FE, Addington-Hall JM, Higginson IJ. End-stage renal disease: a new trajectory of functional decline in the last year of life. J Am Geriatr Soc. 2011;59(2):304–308.

26. Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE. Dialysis or not? A comparative survival study of patients over 75 years with chronic kidney disease stage 5. Nephrol Dial Transplant. 2007;22(7):1955–1962.

27. Cooper BA, Branley P, Bulfone L, et al.; IDEAL Study. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609–619.

28. Moss AH. Improving end-of-life care for dialysis patients. Am J Kidney Dis. 2005;45(1):209–212.

29. Moss AH, Holley JL, Upton MB. Outcomes of cardiopulmonary resuscitation in dialysis patients. J Am Soc Nephrol. 1992;3(6):1238–1243.

30. Moss AH, Hozayen O, King K, Holley JL, Schmidt RJ. Attitudes of patients toward cardiopulmonary resuscitation in the dialysis unit. Am J Kidney Dis. 2001;38(4):847–852.

31. Holley JL. Advance care planning in elderly chronic dialysis patients. Int Urol Nephrol. 2003;35(4):565–568.

32. Holley JL, Hines SC, Glover JJ, Babrow AS, Badzek LA, Moss AH. Failure of advance care planning to elicit patients' preferences for withdrawal from dialysis. Am J Kidney Dis. 1999;33(4):688–693.

33. Davison SN. End-of-life care preferences and needs: perceptions of patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010;5(2):195–204.

34. Bartlow B. In search of an advance directive that works for end-stage renal disease patients. Hemodial Int. 2006;10(suppl 2):S38–S45.

35. Thompson KF, Bhargava J, Bachelder R, Bova-Collis R, Moss AH. Hospice and ESRD: knowledge deficits and underutilization of program benefits. Nephrol Nurs J. 2008;35(5):461–466.

36. Murray AM, Arko C, Chen SC, Gilbertson DT, Moss AH. Use of hospice in the United States dialysis population. Clin J Am Soc Nephrol. 2006;1(6):1248–1255.


Copyright © 2012 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article